April 2024

First And Only FDA-Approved Type Ii Raf Inhibitor For Patients With Relapsed Or Refractory Plgg Harboring A Braf Fusion Or Rearrangement, Or Braf V600 Mutation Made Possible Through PNOC Clinical Trial  FOLLOWING SUCCESSFUL FIREFLY-1 TRIAL IN PARTNERSHIP WITH THE PNOC SCIENTIFIC CONSORTIUM AND DAY

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: